Shares of Regeneron Pharmaceuticals Inc. REGN gained about 2.5% in premarket trading on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Dupixent, the atopic dermatitis therapy developed with Sanofi FR:SAN SNY, for children as young as six months old. European regulators are expected to make a final decision in the coming months. Regeneron’s stock has gained 21.9% over the past year, while the broader S&P 500 SPX is down 6.
... Shares of Regeneron Pharmaceuticals Inc. REGN gained about 2.5% in premarket trading on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Dupixent, the atopic dermatitis therapy developed with Sanofi SAN SNY , for children as young as six months old. European regulators are expected to make a final decision in the coming months. Regeneron’s stock has gained 21.9% over the past year, while the broader S&P 500 SPX is down 6.